Published in Nat Med on November 01, 2001
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol (2004) 1.77
The aftermath of the Merck's HIV vaccine trial. Retrovirology (2008) 1.25
Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. J Virol (2005) 1.24
Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol (2003) 1.06
Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol (2004) 1.01
Cancer-associated CD43 glycoforms as target of immunotherapy. Mol Cancer Ther (2013) 0.88
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One (2008) 0.85
Ultrasensitive rapid detection of human serum antibody biomarkers by biomarker-capturing viral nanofibers. ACS Nano (2015) 0.85
Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells. Virology (2008) 0.84
Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design. Immunome Res (2010) 0.81
Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold. Front Microbiol (2015) 0.81
Synthesis of a trimeric gp120 epitope mimic conjugated to a T-helper peptide to improve antigenicity. J Am Chem Soc (2011) 0.78
Epitope analysis of cerebrospinal fluid IgG in Japanese multiple sclerosis patients using phage display method. Mult Scler Int (2011) 0.77
Delivery strategies for novel vaccine formulations. World J Virol (2012) 0.76
Phages and HIV-1: from display to interplay. Int J Mol Sci (2012) 0.76
Phage display as a promising approach for vaccine development. J Biomed Sci (2016) 0.75
Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines. Viruses (2014) 0.75
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Highly pathogenic H5N1 influenza virus infection in migratory birds. Science (2005) 9.64
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum (1990) 8.92
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 8.36
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum (1990) 8.23
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med (1978) 7.17
7T vs. 4T: RF power, homogeneity, and signal-to-noise comparison in head images. Magn Reson Med (2001) 7.05
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Takayasu arteritis. Ann Intern Med (1994) 5.94
Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest (1974) 4.90
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum (1990) 4.43
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
HIV. An elusive soluble suppressor. Nature (1995) 4.18
Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry (2008) 4.14
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Ia antigen expression on human epidermal Langerhans cells. Nature (1977) 4.05
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (2000) 3.83
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Prevalence and genetic diversity of coronaviruses in bats from China. J Virol (2006) 3.37
Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J (1969) 3.37
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Possible immunological factors in human malignant melanoma in Uganda. Lancet (1967) 3.16
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol (1978) 3.07
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02
Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A (1999) 3.00
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature (1997) 2.94
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Human beta-globin gene expression in transgenic mice is enhanced by a distant DNase I hypersensitive site. Proc Natl Acad Sci U S A (1989) 2.92
Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science (1994) 2.92
Autoimmunization with irradiated tumour cells in human malignant melanoma. Br Med J (1970) 2.91
Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem (1999) 2.89
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med (1979) 2.86
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med (1990) 2.82
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med (1993) 2.81